Armata Pharmaceuticals, Inc.
https://www.armatapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Armata Pharmaceuticals, Inc.
News We're Watching: Tricuspid Procedure Boom, Boston Scientific Borrows $2Bn, And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.
Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
Cormedix Leads Limited Pipeline For US FDA’s LPAD Pathway
Cormedix prepares NDA submission for Neutrolin for prevention of catheter-related blood stream infections, aiming to become the third approval under the US FDA’s Limited Population Pathway.
Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout
Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- C3J Therapeutics, Inc., C3 Jian, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice